201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Cero Therapeutics Enters $750,000 Convertible Promissory Note Agreement
Cero Therapeutics Issues $750,000 Convertible Promissory Note to Keystone Cap...
Clinical Trial of CER-1236 CAR-T Therapy for High-Risk MDS/AML
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
CERo Therapeutics Update on CER-1236 Phase 1 Trial in AML
Stockholders Approve Amendment to CERo Therapeutics 2024 Equity Incentive Plan
Cero Therapeutics Enters $25 Million Common Stock Purchase Agreement
Announces Receipt of Nasdaq Panel Determination
Notice of Late Filing for Annual Report
Q3
Notice of Late Filing for Quarterly Report
Q2
Q1
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement